Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RiBVD · 1 trial · 1 indication
Improvement of progression-free survival (PFS) compared to litterature data 6 months prolongation 24 months compared to 18 months obtained whatever the current regimen and in particular compared to RCHOP regimen in reference with Lenz JCO 2005
| Arm | Type | Description |
|---|---|---|
| RiBVD | EXPERIMENTAL | Rituximab Bendamustine Velcade® Dexamethasone 6 cycles every 28 days |
| Name | Type | Description |
|---|---|---|
| RiBVD | DRUG | Every cycle: Rituximab intravenous infusion dosage 375 mg/m² day 1 Bendamustine direct intervenous 90 mg/m² day 1 and day 2 Velcade®subcutaneous 1,3 mg/m² day 1,4, 8 and 11 dexamethasone 40 mg IVD on day 2 |
Inclusion Criteria: * mantle cell Lymphoma CD20 positive * Untreated patients * 65 ans years old patients or 18 to 65 years old patients who can't or refuse receive conditioning regimen followed by autograft. * Stages Ann Arbor II, III or IV, * ECOG performance status of 0, 1 or 2 * Without history...